|Bid||53.39 x 0|
|Ask||53.47 x 0|
|Day's Range||50.76 - 53.60|
|52 Week Range||31.81 - 76.68|
|Beta (3Y Monthly)||5.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.00|
Canopy Growth Corp.’s much-anticipated lineup of edibles, drinks and vapes could mean higher-than-expected costs for the company, according to analysts at BMO Capital Markets.
On June 24, Cormark Securities cut Canopy Growth's (WEED) (CGC) price target to 65 Canadian dollars from 70 Canadian dollars after the company released its earnings, which largely missed expectations. Cormark maintained its "buy" recommendation on the stock, which was in line with the consensus of the 20 analysts covering the stock.
Canopy Growth (WEED) (CGC) has a strong balance sheet with a cash balance of ~4.5 billion Canadian dollars, which it received from an infusion from Constellation Brands.
Marijuana stocks have been a volatile but largely outperforming group in 2019. But an analyst warns that while some companies are living up to the hype, others have risen too far, too fast.
Canopy Growth stock took a tumble after the Canadian company reported sluggish marijuana sales. Canopy CEO Bruce Linton said in an interview that “massive” margins are coming.
Should investors buy Canopy Growth Corp (TSX:WEED)(NYSE:CGC) on its recent post-earnings dip? Or is it time to take profits for good?
EBITDA is a measure of core performance that tells us about how a company has done in terms of profitability before any effects of charges such as depreciation (noncash charge) and the impact of interest and tax (cash charges).
After Canopy Growth's (WEED) (CGC) release of its fiscal 2019 fourth-quarter earnings results, its price took an 8% dive as its stock went into correction mode. Naturally, this change had an impact on its valuation.
During its earnings call on June 21, Canopy Growth (WEED) (CGC) discussed its ongoing merger and acquisition activities. The company's massive backing of 5 billion Canadian dollars from Constellation Brands (STZ) has provided it with the much-needed resources to build out its growth ambition.
After Canopy Growth's (WEED) (CGC) fiscal 2019 fourth-quarter earnings release, its consensus price target trended lower as analysts adjusted their expectations on the back of its earnings results.
Canopy Growth (WEED) (CGC) held its fiscal 2019 fourth-quarter earnings call on June 21. During the call, it provided critical updates about its near-term performance and growth initiatives. The company's margins took a hit during its most recent quarter. Let's look at what its management had to say.
Canopy Growth (WEED) (CGC), which reported its fiscal 2019 fourth-quarter earnings results on June 20, largely disappointed the market, which led to a sell-off in its stock on June 21, when it fell nearly 7.6%.
Sales are likely to fall short of expectations again unless products such as vape pens and marijuana-spiked beverages don’t provide a quick boost once they are approved for sale in Canada, according to BMO Capital Markets.
Early on June 24, Canopy Growth (WEED) (CGC) announced that Health Canada gave the company a new license to grow cannabis at its outdoor facility in Saskatchewan, Canada, which has a capacity of about seven million square feet (or about 160 acres). This facility will add to the company’s 4,000 acres of existing capacity.
Investing.com - Canopy Growth on Monday extended its slide from last week, as traders continued to mull over the company’s wider-than-expected loss and narrower margins.
The cannabis company's revenue quadrupled, its net loss widened 500%, and its average selling price per gram declined 11% in its fiscal fourth quarter.
The cannabis industry remains under pressure, and Canopy Growth Corp's (TSX:WEED)(NYSE:CGC) recent earnings did little to appease investors.
In the week ending June 21, cannabis stocks were broadly mixed. Aurora Cannabis (ACB) and Canopy Growth (WEED) fell ~4.7% and 3.6%, respectively. Last week, Canopy Growth stock faced pressure.
SMITHS FALLS, ON, June 24, 2019 /CNW Telbec/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED.TO - News) (NYSE:CGC - News) is pleased to announce that it has received a new licence from Health Canada permitting it to grow cannabis at an outdoor site in northern Saskatchewan. Hours after receiving the licence, the first cannabis cuttings were planted at a 7 million sq. ft. (160 acres) secure cultivation field in the province, one that is patrolled by drones (kidding – no drones, promise.) The new licence expands Canopy Growth's diversified Canadian footprint and complements its existing indoor and greenhouse facilities to provide a leading balance of facilities to produce low cost input materials for value-add products, while ensuring more sophisticated growing operations for in-demand flower products.